Drugs / GRI-0621
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02949375 Comparator | Sep 2015 → Nov 2018 | liver disorder | GRI Bio Operations, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRI-0621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02949375 ↗ |
| Route | Oral | “The investigational product will be administered orally once daily in the morning” NCT02949375 ↗ |